Sanos Bioscience raises major investment  

The biotech company has raised DKK 60 million from Swedish venture funds to start clinical tests of a product for treatment of osteoporosis

Sanos Bioscience, a spin-off from biotech company Nordic Bioscience, has raised DKK 60 million (USD 10.2 million) from the Swedish venture funds Scandinavian Life Science Venture and SEB Företagsinvest. Sanos Bioscience will use the money to start clinical tests of a peptide, GLP-2, for treatment of osteoporosis. The tests are expected to start during 2004/2005.


The clinical development of GLP-2 builds on positive results from studies in postmenopausal women. Sanos Bioscience is aiming to develop a method which can both prevent and treat osteoporosis. The method reportedly prevents bone decalcification as well as having a bone regenerating effect. Sanos Bioscience uses a scientific platform developed by Nordic Bioscience. The news is reported by BiotechDenmark online.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×